Bluebird Bio initiated with a Neutral at Cantor Fitzgerald
The Fly

Bluebird Bio initiated with a Neutral at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Bluebird Bio (BLUE) with a Neutral rating and no price target. Cantor expects Bluebird’s lovo-cel to be approved on or around its PDUFA date and believes its profile is more similar than different from Vertex (VRTX) and Crispr’s (CRSP) exa-cel, but feels cell therapies face multiple barriers to penetrating the sickle cell disorder market, the analyst tells investors in a research note. Cantor adds that Bluebird’s resource constraints could place lovo-cel at a competitive disadvantage.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on BLUE:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App